Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for subject:(Phase I clinical trial). Showing records 1 – 30 of 46361 total matches.

[1] [2] [3] [4] [5] … [1546]

Search Limiters

Last 2 Years | English Only

Degrees

Languages

Country

▼ Search Limiters


University of Southern California

1. Venkatramani, Rajkumar. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin.

Degree: MS, Preventive Medicine (Health Behavior), 2010, University of Southern California

 Vincristine, irinotecan and temozolomide have been used in various combinations to treat pediatric solid tumors. These combinations, in general have been well tolerated. Outcomes for… (more)

Subjects/Keywords: phase I study; clinical trial; bevacizumab

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Venkatramani, R. (2010). A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin. (Masters Thesis). University of Southern California. Retrieved from http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/409812/rec/296

Chicago Manual of Style (16th Edition):

Venkatramani, Rajkumar. “A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin.” 2010. Masters Thesis, University of Southern California. Accessed January 20, 2020. http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/409812/rec/296.

MLA Handbook (7th Edition):

Venkatramani, Rajkumar. “A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin.” 2010. Web. 20 Jan 2020.

Vancouver:

Venkatramani R. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin. [Internet] [Masters thesis]. University of Southern California; 2010. [cited 2020 Jan 20]. Available from: http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/409812/rec/296.

Council of Science Editors:

Venkatramani R. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin. [Masters Thesis]. University of Southern California; 2010. Available from: http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/409812/rec/296


Boston University

2. Malesz, Alexandra Elizabeth. Pemetrexed in primary central nervous system lymphoma: a phase-I dose finding study.

Degree: MS, Medical Sciences, 2016, Boston University

 OBJECTIVE: The aim of this study was to investigate the safety and tolerability of a novel anti-folate drug, pemetrexed, in the setting of a phase(more)

Subjects/Keywords: Oncology; Pemetrexed; Phase I clinical trial; Primary CNS lymphoma

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Malesz, A. E. (2016). Pemetrexed in primary central nervous system lymphoma: a phase-I dose finding study. (Masters Thesis). Boston University. Retrieved from http://hdl.handle.net/2144/19487

Chicago Manual of Style (16th Edition):

Malesz, Alexandra Elizabeth. “Pemetrexed in primary central nervous system lymphoma: a phase-I dose finding study.” 2016. Masters Thesis, Boston University. Accessed January 20, 2020. http://hdl.handle.net/2144/19487.

MLA Handbook (7th Edition):

Malesz, Alexandra Elizabeth. “Pemetrexed in primary central nervous system lymphoma: a phase-I dose finding study.” 2016. Web. 20 Jan 2020.

Vancouver:

Malesz AE. Pemetrexed in primary central nervous system lymphoma: a phase-I dose finding study. [Internet] [Masters thesis]. Boston University; 2016. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/2144/19487.

Council of Science Editors:

Malesz AE. Pemetrexed in primary central nervous system lymphoma: a phase-I dose finding study. [Masters Thesis]. Boston University; 2016. Available from: http://hdl.handle.net/2144/19487

3. AndrÃa Vieira Pontes Rohleder. Estudo fase I para avaliar a seguranÃa e tolerabilidade do LABCAT TCJUSS administrado por via oral em voluntÃrios sadios do sexo masculino.

Degree: PhD, 2014, Universidade Federal do Ceará

O ensaio clÃnico fase I Ã a primeira etapa de teste de medicamentos em seres humanos, visando determinar principalmente a seguranÃa associada a doses crescentes… (more)

Subjects/Keywords: FARMACOLOGIA; Ensaio ClÃnico Fase I; SeguranÃa; Efeitos adversos; Clinical Trial, Phase I; Safety; Adverse effects

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Rohleder, A. V. P. (2014). Estudo fase I para avaliar a seguranÃa e tolerabilidade do LABCAT TCJUSS administrado por via oral em voluntÃrios sadios do sexo masculino. (Doctoral Dissertation). Universidade Federal do Ceará. Retrieved from http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=13615 ;

Chicago Manual of Style (16th Edition):

Rohleder, AndrÃa Vieira Pontes. “Estudo fase I para avaliar a seguranÃa e tolerabilidade do LABCAT TCJUSS administrado por via oral em voluntÃrios sadios do sexo masculino.” 2014. Doctoral Dissertation, Universidade Federal do Ceará. Accessed January 20, 2020. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=13615 ;.

MLA Handbook (7th Edition):

Rohleder, AndrÃa Vieira Pontes. “Estudo fase I para avaliar a seguranÃa e tolerabilidade do LABCAT TCJUSS administrado por via oral em voluntÃrios sadios do sexo masculino.” 2014. Web. 20 Jan 2020.

Vancouver:

Rohleder AVP. Estudo fase I para avaliar a seguranÃa e tolerabilidade do LABCAT TCJUSS administrado por via oral em voluntÃrios sadios do sexo masculino. [Internet] [Doctoral dissertation]. Universidade Federal do Ceará 2014. [cited 2020 Jan 20]. Available from: http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=13615 ;.

Council of Science Editors:

Rohleder AVP. Estudo fase I para avaliar a seguranÃa e tolerabilidade do LABCAT TCJUSS administrado por via oral em voluntÃrios sadios do sexo masculino. [Doctoral Dissertation]. Universidade Federal do Ceará 2014. Available from: http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=13615 ;


University of Louisville

4. Ray, Herman E. Design and inference in phase II/III clinical trials incorporating monitoring of multiple endpoints.

Degree: PhD, 2011, University of Louisville

 The phase II clinical trial is a critical step in the drug development process. In the oncology setting, phase II studies typically evaluate one primary… (more)

Subjects/Keywords: Clinical trial; Bivariate; Phase II; Phase III

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Ray, H. E. (2011). Design and inference in phase II/III clinical trials incorporating monitoring of multiple endpoints. (Doctoral Dissertation). University of Louisville. Retrieved from 10.18297/etd/1189 ; https://ir.library.louisville.edu/etd/1189

Chicago Manual of Style (16th Edition):

Ray, Herman E. “Design and inference in phase II/III clinical trials incorporating monitoring of multiple endpoints.” 2011. Doctoral Dissertation, University of Louisville. Accessed January 20, 2020. 10.18297/etd/1189 ; https://ir.library.louisville.edu/etd/1189.

MLA Handbook (7th Edition):

Ray, Herman E. “Design and inference in phase II/III clinical trials incorporating monitoring of multiple endpoints.” 2011. Web. 20 Jan 2020.

Vancouver:

Ray HE. Design and inference in phase II/III clinical trials incorporating monitoring of multiple endpoints. [Internet] [Doctoral dissertation]. University of Louisville; 2011. [cited 2020 Jan 20]. Available from: 10.18297/etd/1189 ; https://ir.library.louisville.edu/etd/1189.

Council of Science Editors:

Ray HE. Design and inference in phase II/III clinical trials incorporating monitoring of multiple endpoints. [Doctoral Dissertation]. University of Louisville; 2011. Available from: 10.18297/etd/1189 ; https://ir.library.louisville.edu/etd/1189


Texas Medical Center

5. Piha-Paul, Sarina A. An Innovative Phase I Trial Design Allowing for the Identification of Multiple Potential Maximum Tolerated Doses with Combination Therapy of Targeted Agents.

Degree: MS, 2010, Texas Medical Center

 Treatment for cancer often involves combination therapies used both in medical practice and clinical trials. Korn and Simon listed three reasons for the utility of… (more)

Subjects/Keywords: phase I; trial design; bevacizumab. temsirolimus; Oncology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Piha-Paul, S. A. (2010). An Innovative Phase I Trial Design Allowing for the Identification of Multiple Potential Maximum Tolerated Doses with Combination Therapy of Targeted Agents. (Masters Thesis). Texas Medical Center. Retrieved from http://digitalcommons.library.tmc.edu/utgsbs_dissertations/72

Chicago Manual of Style (16th Edition):

Piha-Paul, Sarina A. “An Innovative Phase I Trial Design Allowing for the Identification of Multiple Potential Maximum Tolerated Doses with Combination Therapy of Targeted Agents.” 2010. Masters Thesis, Texas Medical Center. Accessed January 20, 2020. http://digitalcommons.library.tmc.edu/utgsbs_dissertations/72.

MLA Handbook (7th Edition):

Piha-Paul, Sarina A. “An Innovative Phase I Trial Design Allowing for the Identification of Multiple Potential Maximum Tolerated Doses with Combination Therapy of Targeted Agents.” 2010. Web. 20 Jan 2020.

Vancouver:

Piha-Paul SA. An Innovative Phase I Trial Design Allowing for the Identification of Multiple Potential Maximum Tolerated Doses with Combination Therapy of Targeted Agents. [Internet] [Masters thesis]. Texas Medical Center; 2010. [cited 2020 Jan 20]. Available from: http://digitalcommons.library.tmc.edu/utgsbs_dissertations/72.

Council of Science Editors:

Piha-Paul SA. An Innovative Phase I Trial Design Allowing for the Identification of Multiple Potential Maximum Tolerated Doses with Combination Therapy of Targeted Agents. [Masters Thesis]. Texas Medical Center; 2010. Available from: http://digitalcommons.library.tmc.edu/utgsbs_dissertations/72

6. Jader Freire Sobral Filho. Pharmacological clinical trial phase I and II with the hydrogel obtained from the ethanol crude extract of the bark of Anacardium occidentale Linn. in the treatment of acne vulgaris.

Degree: 2010, Universidade Federal da Paraíba

The acne vulgaris is the most prevalent dermatologic disease of teen age. Many drugs are used in the treatment of acne but it is necessary… (more)

Subjects/Keywords: clinical trial phase I and II; FARMACOLOGIA; acne vulgaris; Anacardium occidentale Linn.; acne vulgar e ensaios clínicos de fases I e II; Anacardium occidentale Linn.

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Filho, J. F. S. (2010). Pharmacological clinical trial phase I and II with the hydrogel obtained from the ethanol crude extract of the bark of Anacardium occidentale Linn. in the treatment of acne vulgaris. (Thesis). Universidade Federal da Paraíba. Retrieved from http://bdtd.biblioteca.ufpb.br/tde_busca/arquivo.php?codArquivo=1232

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Filho, Jader Freire Sobral. “Pharmacological clinical trial phase I and II with the hydrogel obtained from the ethanol crude extract of the bark of Anacardium occidentale Linn. in the treatment of acne vulgaris.” 2010. Thesis, Universidade Federal da Paraíba. Accessed January 20, 2020. http://bdtd.biblioteca.ufpb.br/tde_busca/arquivo.php?codArquivo=1232.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Filho, Jader Freire Sobral. “Pharmacological clinical trial phase I and II with the hydrogel obtained from the ethanol crude extract of the bark of Anacardium occidentale Linn. in the treatment of acne vulgaris.” 2010. Web. 20 Jan 2020.

Vancouver:

Filho JFS. Pharmacological clinical trial phase I and II with the hydrogel obtained from the ethanol crude extract of the bark of Anacardium occidentale Linn. in the treatment of acne vulgaris. [Internet] [Thesis]. Universidade Federal da Paraíba; 2010. [cited 2020 Jan 20]. Available from: http://bdtd.biblioteca.ufpb.br/tde_busca/arquivo.php?codArquivo=1232.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Filho JFS. Pharmacological clinical trial phase I and II with the hydrogel obtained from the ethanol crude extract of the bark of Anacardium occidentale Linn. in the treatment of acne vulgaris. [Thesis]. Universidade Federal da Paraíba; 2010. Available from: http://bdtd.biblioteca.ufpb.br/tde_busca/arquivo.php?codArquivo=1232

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Southern California

7. Chen, Zhengjia. Phase I clinical trial designs: range and trend of expected toxicity level in standard A+B designs and an extended isotonic design treating toxicity as a quasi-continuous variable.

Degree: PhD, Biostatistics, 2009, University of Southern California

 The current designs of Phase I trials are comprehensively reviewed and classified by algorithm (assumption and dose-toxicity relationship) as rule based designs vs model based… (more)

Subjects/Keywords: phase I clinical trial designs; isotonic regression; maximum tolerated dosage; extended isotonic design; quasi-continuous variable; dose limiting toxicity; binary indicator; toxicity response

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Chen, Z. (2009). Phase I clinical trial designs: range and trend of expected toxicity level in standard A+B designs and an extended isotonic design treating toxicity as a quasi-continuous variable. (Doctoral Dissertation). University of Southern California. Retrieved from http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/151232/rec/5026

Chicago Manual of Style (16th Edition):

Chen, Zhengjia. “Phase I clinical trial designs: range and trend of expected toxicity level in standard A+B designs and an extended isotonic design treating toxicity as a quasi-continuous variable.” 2009. Doctoral Dissertation, University of Southern California. Accessed January 20, 2020. http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/151232/rec/5026.

MLA Handbook (7th Edition):

Chen, Zhengjia. “Phase I clinical trial designs: range and trend of expected toxicity level in standard A+B designs and an extended isotonic design treating toxicity as a quasi-continuous variable.” 2009. Web. 20 Jan 2020.

Vancouver:

Chen Z. Phase I clinical trial designs: range and trend of expected toxicity level in standard A+B designs and an extended isotonic design treating toxicity as a quasi-continuous variable. [Internet] [Doctoral dissertation]. University of Southern California; 2009. [cited 2020 Jan 20]. Available from: http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/151232/rec/5026.

Council of Science Editors:

Chen Z. Phase I clinical trial designs: range and trend of expected toxicity level in standard A+B designs and an extended isotonic design treating toxicity as a quasi-continuous variable. [Doctoral Dissertation]. University of Southern California; 2009. Available from: http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/151232/rec/5026


Freie Universität Berlin

8. Rohde, Laura. Analyse der Wirksamkeit eines neuen zytotoxischen Prodrugs, CAP7.1, in einer Phase-I-Studie an Patienten mit therapierefraktären soliden Tumoren.

Degree: 2016, Freie Universität Berlin

 Ziel dieser Arbeit ist die Analyse und Bewertung der initialen Wirksamkeit von CAP7.1, einer neuen zytotoxischen Substanz, welche kürzlich in einer Phase-I-Studie an Patienten mit… (more)

Subjects/Keywords: CAP7.1; phase I; etoposid; efficacy; ProVP-16; cytotoxic; chemotherapy; clinical trial; tumour; cancer; prodrug; carboxylesteras; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Rohde, L. (2016). Analyse der Wirksamkeit eines neuen zytotoxischen Prodrugs, CAP7.1, in einer Phase-I-Studie an Patienten mit therapierefraktären soliden Tumoren. (Thesis). Freie Universität Berlin. Retrieved from https://refubium.fu-berlin.de/handle/fub188/11333

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Rohde, Laura. “Analyse der Wirksamkeit eines neuen zytotoxischen Prodrugs, CAP7.1, in einer Phase-I-Studie an Patienten mit therapierefraktären soliden Tumoren.” 2016. Thesis, Freie Universität Berlin. Accessed January 20, 2020. https://refubium.fu-berlin.de/handle/fub188/11333.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Rohde, Laura. “Analyse der Wirksamkeit eines neuen zytotoxischen Prodrugs, CAP7.1, in einer Phase-I-Studie an Patienten mit therapierefraktären soliden Tumoren.” 2016. Web. 20 Jan 2020.

Vancouver:

Rohde L. Analyse der Wirksamkeit eines neuen zytotoxischen Prodrugs, CAP7.1, in einer Phase-I-Studie an Patienten mit therapierefraktären soliden Tumoren. [Internet] [Thesis]. Freie Universität Berlin; 2016. [cited 2020 Jan 20]. Available from: https://refubium.fu-berlin.de/handle/fub188/11333.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Rohde L. Analyse der Wirksamkeit eines neuen zytotoxischen Prodrugs, CAP7.1, in einer Phase-I-Studie an Patienten mit therapierefraktären soliden Tumoren. [Thesis]. Freie Universität Berlin; 2016. Available from: https://refubium.fu-berlin.de/handle/fub188/11333

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Vanderbilt University

9. Olson, Molly Ann. A Comparison of Approaches for Unplanned Sample Size Changes in Phase II Clinical Trials.

Degree: MS, Biostatistics, 2017, Vanderbilt University

 Oncology phase II clinical trials are used to evaluate the initial effect of a new regimen to determine if there warrants further study in a… (more)

Subjects/Keywords: sample size deviations; likelihood; frequentist; phase II; clinical trial; two-stage

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Olson, M. A. (2017). A Comparison of Approaches for Unplanned Sample Size Changes in Phase II Clinical Trials. (Masters Thesis). Vanderbilt University. Retrieved from http://etd.library.vanderbilt.edu/available/etd-06132017-150729/ ;

Chicago Manual of Style (16th Edition):

Olson, Molly Ann. “A Comparison of Approaches for Unplanned Sample Size Changes in Phase II Clinical Trials.” 2017. Masters Thesis, Vanderbilt University. Accessed January 20, 2020. http://etd.library.vanderbilt.edu/available/etd-06132017-150729/ ;.

MLA Handbook (7th Edition):

Olson, Molly Ann. “A Comparison of Approaches for Unplanned Sample Size Changes in Phase II Clinical Trials.” 2017. Web. 20 Jan 2020.

Vancouver:

Olson MA. A Comparison of Approaches for Unplanned Sample Size Changes in Phase II Clinical Trials. [Internet] [Masters thesis]. Vanderbilt University; 2017. [cited 2020 Jan 20]. Available from: http://etd.library.vanderbilt.edu/available/etd-06132017-150729/ ;.

Council of Science Editors:

Olson MA. A Comparison of Approaches for Unplanned Sample Size Changes in Phase II Clinical Trials. [Masters Thesis]. Vanderbilt University; 2017. Available from: http://etd.library.vanderbilt.edu/available/etd-06132017-150729/ ;


Université Paris-Sud – Paris XI

10. Doussau de Bazignan, Adélaïde. Essais cliniques de recherche de dose en oncologie : d'un schéma d'essai permettant l'inclusion continue à l’utilisation des données longitudinales de toxicité : Dose-finding clinical trials in oncology : from continuous enrolment, to the integration of repeated toxicity measurements.

Degree: Docteur es, Santé Publique, option Recherche Clinique, 2014, Université Paris-Sud – Paris XI

L’objectif des essais de phase I en oncologie est d’identifier la dose maximale tolérée (DMT). Le schéma « 3+3 » nécessite d’interrompre les inclusions en… (more)

Subjects/Keywords: Essais cliniques adaptatifs; Essais de recherche de dose; Phase I; Modèle à cotes proportionnelles; Modèles à effet aléatoire; Oncologie; Adaptive clinical trial; Dose-finding trials; Phase I; Proportional odds model; Mixed models; Oncology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Doussau de Bazignan, A. (2014). Essais cliniques de recherche de dose en oncologie : d'un schéma d'essai permettant l'inclusion continue à l’utilisation des données longitudinales de toxicité : Dose-finding clinical trials in oncology : from continuous enrolment, to the integration of repeated toxicity measurements. (Doctoral Dissertation). Université Paris-Sud – Paris XI. Retrieved from http://www.theses.fr/2014PA11T013

Chicago Manual of Style (16th Edition):

Doussau de Bazignan, Adélaïde. “Essais cliniques de recherche de dose en oncologie : d'un schéma d'essai permettant l'inclusion continue à l’utilisation des données longitudinales de toxicité : Dose-finding clinical trials in oncology : from continuous enrolment, to the integration of repeated toxicity measurements.” 2014. Doctoral Dissertation, Université Paris-Sud – Paris XI. Accessed January 20, 2020. http://www.theses.fr/2014PA11T013.

MLA Handbook (7th Edition):

Doussau de Bazignan, Adélaïde. “Essais cliniques de recherche de dose en oncologie : d'un schéma d'essai permettant l'inclusion continue à l’utilisation des données longitudinales de toxicité : Dose-finding clinical trials in oncology : from continuous enrolment, to the integration of repeated toxicity measurements.” 2014. Web. 20 Jan 2020.

Vancouver:

Doussau de Bazignan A. Essais cliniques de recherche de dose en oncologie : d'un schéma d'essai permettant l'inclusion continue à l’utilisation des données longitudinales de toxicité : Dose-finding clinical trials in oncology : from continuous enrolment, to the integration of repeated toxicity measurements. [Internet] [Doctoral dissertation]. Université Paris-Sud – Paris XI; 2014. [cited 2020 Jan 20]. Available from: http://www.theses.fr/2014PA11T013.

Council of Science Editors:

Doussau de Bazignan A. Essais cliniques de recherche de dose en oncologie : d'un schéma d'essai permettant l'inclusion continue à l’utilisation des données longitudinales de toxicité : Dose-finding clinical trials in oncology : from continuous enrolment, to the integration of repeated toxicity measurements. [Doctoral Dissertation]. Université Paris-Sud – Paris XI; 2014. Available from: http://www.theses.fr/2014PA11T013


Universitat Autònoma de Barcelona

11. Macarulla Mercadé, Teresa. Análisis molecular en tumores de páncreas avanzados para identificar biomarcadores predictivos de respuesta a nuevas drogas biológicas.

Degree: Departament de Medicina, 2015, Universitat Autònoma de Barcelona

 Pancreatic cancer presented a dismal prognosis. During the last years an efford has been done in order to improve the results of the chemotherapy in… (more)

Subjects/Keywords: Càncer de pancrees; Cáncer de páncreas; Pancreatic cancer; Mutació de KRAS; Mutación de KRAS; KRAS mutation; Estudi fase I; Estudio fase I; Phase I clinical trial; Ciències de la Salut; 61

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Macarulla Mercadé, T. (2015). Análisis molecular en tumores de páncreas avanzados para identificar biomarcadores predictivos de respuesta a nuevas drogas biológicas. (Thesis). Universitat Autònoma de Barcelona. Retrieved from http://hdl.handle.net/10803/377464

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Macarulla Mercadé, Teresa. “Análisis molecular en tumores de páncreas avanzados para identificar biomarcadores predictivos de respuesta a nuevas drogas biológicas.” 2015. Thesis, Universitat Autònoma de Barcelona. Accessed January 20, 2020. http://hdl.handle.net/10803/377464.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Macarulla Mercadé, Teresa. “Análisis molecular en tumores de páncreas avanzados para identificar biomarcadores predictivos de respuesta a nuevas drogas biológicas.” 2015. Web. 20 Jan 2020.

Vancouver:

Macarulla Mercadé T. Análisis molecular en tumores de páncreas avanzados para identificar biomarcadores predictivos de respuesta a nuevas drogas biológicas. [Internet] [Thesis]. Universitat Autònoma de Barcelona; 2015. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/10803/377464.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Macarulla Mercadé T. Análisis molecular en tumores de páncreas avanzados para identificar biomarcadores predictivos de respuesta a nuevas drogas biológicas. [Thesis]. Universitat Autònoma de Barcelona; 2015. Available from: http://hdl.handle.net/10803/377464

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

12. Esnault, Olivier. Thérapeutique par ultrasons focalisés de haute intensité (HIFU) appliquée à la thyroïde : de l’expérimentation animale à l’essai humain : -.

Degree: Docteur es, Biologie humaine. recherche clinique, 2009, Université Claude Bernard – Lyon I

La grande fréquence des nodules thyroïdiens et la relative agressivité des traitements conventionnels ont motivé l'étude d'une méthode non invasive utilisant des Ultrasons Focalisés (HIFU).… (more)

Subjects/Keywords: HIFU; Brebis; Essai animal; Essai de phase I; Nodule thyroïdien; HIFU; Ewe; Animal test; Phase I trial; Thyroid nodule; 610

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Esnault, O. (2009). Thérapeutique par ultrasons focalisés de haute intensité (HIFU) appliquée à la thyroïde : de l’expérimentation animale à l’essai humain : -. (Doctoral Dissertation). Université Claude Bernard – Lyon I. Retrieved from http://www.theses.fr/2009LYO10340

Chicago Manual of Style (16th Edition):

Esnault, Olivier. “Thérapeutique par ultrasons focalisés de haute intensité (HIFU) appliquée à la thyroïde : de l’expérimentation animale à l’essai humain : -.” 2009. Doctoral Dissertation, Université Claude Bernard – Lyon I. Accessed January 20, 2020. http://www.theses.fr/2009LYO10340.

MLA Handbook (7th Edition):

Esnault, Olivier. “Thérapeutique par ultrasons focalisés de haute intensité (HIFU) appliquée à la thyroïde : de l’expérimentation animale à l’essai humain : -.” 2009. Web. 20 Jan 2020.

Vancouver:

Esnault O. Thérapeutique par ultrasons focalisés de haute intensité (HIFU) appliquée à la thyroïde : de l’expérimentation animale à l’essai humain : -. [Internet] [Doctoral dissertation]. Université Claude Bernard – Lyon I; 2009. [cited 2020 Jan 20]. Available from: http://www.theses.fr/2009LYO10340.

Council of Science Editors:

Esnault O. Thérapeutique par ultrasons focalisés de haute intensité (HIFU) appliquée à la thyroïde : de l’expérimentation animale à l’essai humain : -. [Doctoral Dissertation]. Université Claude Bernard – Lyon I; 2009. Available from: http://www.theses.fr/2009LYO10340


Université de Montréal

13. Kabawat, Marla. Phase-I clinical trial on the effect of palatal brushing on denture stomatitis .

Degree: 2014, Université de Montréal

 Introduction: La stomatite prothétique est une condition inflammatoire chronique de la muqueuse buccale recouverte par une prothèse. Cette maladie est considérée comme la lésion buccale… (more)

Subjects/Keywords: Stomatite prothétique; Brossage du palais; Prothèse complète; Candida; Étude de phase I; Denture stomatitis; Palatal brushing; Complete denture; Phase I trial

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Kabawat, M. (2014). Phase-I clinical trial on the effect of palatal brushing on denture stomatitis . (Thesis). Université de Montréal. Retrieved from http://hdl.handle.net/1866/10371

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Kabawat, Marla. “Phase-I clinical trial on the effect of palatal brushing on denture stomatitis .” 2014. Thesis, Université de Montréal. Accessed January 20, 2020. http://hdl.handle.net/1866/10371.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Kabawat, Marla. “Phase-I clinical trial on the effect of palatal brushing on denture stomatitis .” 2014. Web. 20 Jan 2020.

Vancouver:

Kabawat M. Phase-I clinical trial on the effect of palatal brushing on denture stomatitis . [Internet] [Thesis]. Université de Montréal; 2014. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/1866/10371.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Kabawat M. Phase-I clinical trial on the effect of palatal brushing on denture stomatitis . [Thesis]. Université de Montréal; 2014. Available from: http://hdl.handle.net/1866/10371

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

14. Cavalli, Maide Maria. Predicting survival outcomes in Myeloma using surrogate markers.

Degree: 2013, Università degli Studi di Catania

 BACKGROUND: OS should be considered the gold standard before adopting a particular treatment strategy as standard of care in Multiple Myeloma Phase III randomized clinical(more)

Subjects/Keywords: Area 06 - Scienze mediche; Multiple Myeloma,Randomized clinical trial,phase III/3

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Cavalli, M. M. (2013). Predicting survival outcomes in Myeloma using surrogate markers. (Thesis). Università degli Studi di Catania. Retrieved from http://hdl.handle.net/10761/1394

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Cavalli, Maide Maria. “Predicting survival outcomes in Myeloma using surrogate markers.” 2013. Thesis, Università degli Studi di Catania. Accessed January 20, 2020. http://hdl.handle.net/10761/1394.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Cavalli, Maide Maria. “Predicting survival outcomes in Myeloma using surrogate markers.” 2013. Web. 20 Jan 2020.

Vancouver:

Cavalli MM. Predicting survival outcomes in Myeloma using surrogate markers. [Internet] [Thesis]. Università degli Studi di Catania; 2013. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/10761/1394.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Cavalli MM. Predicting survival outcomes in Myeloma using surrogate markers. [Thesis]. Università degli Studi di Catania; 2013. Available from: http://hdl.handle.net/10761/1394

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Boston University

15. Wang, Jing. Biomarker informed adaptive clinical trial designs.

Degree: PhD, Biostatistics, 2014, Boston University

 In adaptive design clinical trials, an endpoint at the final analysis that takes a long time to observe is not feasible to be used for… (more)

Subjects/Keywords: Biostatistics; Biomarker; Dose-response; Power; Type I error; Adaptive design; Clinical trial

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Wang, J. (2014). Biomarker informed adaptive clinical trial designs. (Doctoral Dissertation). Boston University. Retrieved from http://hdl.handle.net/2144/14281

Chicago Manual of Style (16th Edition):

Wang, Jing. “Biomarker informed adaptive clinical trial designs.” 2014. Doctoral Dissertation, Boston University. Accessed January 20, 2020. http://hdl.handle.net/2144/14281.

MLA Handbook (7th Edition):

Wang, Jing. “Biomarker informed adaptive clinical trial designs.” 2014. Web. 20 Jan 2020.

Vancouver:

Wang J. Biomarker informed adaptive clinical trial designs. [Internet] [Doctoral dissertation]. Boston University; 2014. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/2144/14281.

Council of Science Editors:

Wang J. Biomarker informed adaptive clinical trial designs. [Doctoral Dissertation]. Boston University; 2014. Available from: http://hdl.handle.net/2144/14281


Université Paris-Sud – Paris XI

16. Tournoux-Facon, Caroline. Contribuer à l’amélioration du ciblage thérapeutique en oncologie par une nouvelle méthodologie des essais de phase II : A new methodology for phase II trials to improve therapeutic targeting in oncology.

Degree: Docteur es, Recherche clinique, 2012, Université Paris-Sud – Paris XI

On constate que la majorité des essais de phase III, conduits après des essais de phase II pourtant prometteurs, sont “négatifs”, la nouvelle thérapeutique se… (more)

Subjects/Keywords: Essai de phase II; Hétérogénéité de la population; Stratification; Ciblage thérapeutique; Phase II clinical trial; Population heterogeneity; Stratification; Therapeutic targeting

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Tournoux-Facon, C. (2012). Contribuer à l’amélioration du ciblage thérapeutique en oncologie par une nouvelle méthodologie des essais de phase II : A new methodology for phase II trials to improve therapeutic targeting in oncology. (Doctoral Dissertation). Université Paris-Sud – Paris XI. Retrieved from http://www.theses.fr/2012PA11T062

Chicago Manual of Style (16th Edition):

Tournoux-Facon, Caroline. “Contribuer à l’amélioration du ciblage thérapeutique en oncologie par une nouvelle méthodologie des essais de phase II : A new methodology for phase II trials to improve therapeutic targeting in oncology.” 2012. Doctoral Dissertation, Université Paris-Sud – Paris XI. Accessed January 20, 2020. http://www.theses.fr/2012PA11T062.

MLA Handbook (7th Edition):

Tournoux-Facon, Caroline. “Contribuer à l’amélioration du ciblage thérapeutique en oncologie par une nouvelle méthodologie des essais de phase II : A new methodology for phase II trials to improve therapeutic targeting in oncology.” 2012. Web. 20 Jan 2020.

Vancouver:

Tournoux-Facon C. Contribuer à l’amélioration du ciblage thérapeutique en oncologie par une nouvelle méthodologie des essais de phase II : A new methodology for phase II trials to improve therapeutic targeting in oncology. [Internet] [Doctoral dissertation]. Université Paris-Sud – Paris XI; 2012. [cited 2020 Jan 20]. Available from: http://www.theses.fr/2012PA11T062.

Council of Science Editors:

Tournoux-Facon C. Contribuer à l’amélioration du ciblage thérapeutique en oncologie par une nouvelle méthodologie des essais de phase II : A new methodology for phase II trials to improve therapeutic targeting in oncology. [Doctoral Dissertation]. Université Paris-Sud – Paris XI; 2012. Available from: http://www.theses.fr/2012PA11T062


Baylor University

17. Pruszynski, Jessica E. Bayesian models for discrete censored sampling and dose finding.

Degree: Statistical Sciences., 2010, Baylor University

 We first consider the problem of discrete censored sampling. Censored binomial data may lead to irregular likelihood functions and problems with statistical inference. We consider… (more)

Subjects/Keywords: Bayesian methods.; Discrete censored sampling.; Phase I clinical trials.

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Pruszynski, J. E. (2010). Bayesian models for discrete censored sampling and dose finding. (Thesis). Baylor University. Retrieved from http://hdl.handle.net/2104/7959

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Pruszynski, Jessica E. “Bayesian models for discrete censored sampling and dose finding. ” 2010. Thesis, Baylor University. Accessed January 20, 2020. http://hdl.handle.net/2104/7959.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Pruszynski, Jessica E. “Bayesian models for discrete censored sampling and dose finding. ” 2010. Web. 20 Jan 2020.

Vancouver:

Pruszynski JE. Bayesian models for discrete censored sampling and dose finding. [Internet] [Thesis]. Baylor University; 2010. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/2104/7959.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Pruszynski JE. Bayesian models for discrete censored sampling and dose finding. [Thesis]. Baylor University; 2010. Available from: http://hdl.handle.net/2104/7959

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

18. Cui, Ye. Advanced Designs of Cancer Phase I and Phase II Clinical Trials.

Degree: PhD, Mathematics and Statistics, 2013, Georgia State University

  The clinical trial is the most import study for the development of successful novel drugs. The aim of this dissertation is to develop innovative… (more)

Subjects/Keywords: Clinical trial design; Phase I; Phase II; Maximum tolerated dose (MTD); Adaptive design; Personalized MTD; Covariate effect; Two-stage design; Success rate; Trial efficiency

…common phase I clinical trial designs… …part of cancer phase I and phase II clinical trial designs. The first part of this… …curative effect. Usually, the number of subjects in a phase I clinical trial is relatively small… …dissertation. Table 2.2 Terms in common phase I clinical trial designs Term Definition Cohort Group… …presentation, I would not have pursued the study of clinical trial design. I would like to thank my… 

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Cui, Y. (2013). Advanced Designs of Cancer Phase I and Phase II Clinical Trials. (Doctoral Dissertation). Georgia State University. Retrieved from https://scholarworks.gsu.edu/math_diss/15

Chicago Manual of Style (16th Edition):

Cui, Ye. “Advanced Designs of Cancer Phase I and Phase II Clinical Trials.” 2013. Doctoral Dissertation, Georgia State University. Accessed January 20, 2020. https://scholarworks.gsu.edu/math_diss/15.

MLA Handbook (7th Edition):

Cui, Ye. “Advanced Designs of Cancer Phase I and Phase II Clinical Trials.” 2013. Web. 20 Jan 2020.

Vancouver:

Cui Y. Advanced Designs of Cancer Phase I and Phase II Clinical Trials. [Internet] [Doctoral dissertation]. Georgia State University; 2013. [cited 2020 Jan 20]. Available from: https://scholarworks.gsu.edu/math_diss/15.

Council of Science Editors:

Cui Y. Advanced Designs of Cancer Phase I and Phase II Clinical Trials. [Doctoral Dissertation]. Georgia State University; 2013. Available from: https://scholarworks.gsu.edu/math_diss/15


University of Lund

19. Leon, Otilia. Improved oncological treatment of anal cancer.

Degree: 2019, University of Lund

 AbstractBackground: Squamous cell cancer of the anus (SCCA) is a rare malignancy, but the incidence is increasing. It isassociated with humman papilloma virus infection. The… (more)

Subjects/Keywords: Medical and Health Sciences; Anal cancer; chemotherapy; Radiotherapy; Prognosis and survival; phase I/II trial; Cetuximab; metastatic

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Leon, O. (2019). Improved oncological treatment of anal cancer. (Doctoral Dissertation). University of Lund. Retrieved from http://lup.lub.lu.se/record/fb100283-a48a-4886-88c3-c5654d33b5a3 ; https://portal.research.lu.se/ws/files/61679568/Improved_oncological_treatment_of_anal_cancer_Otilia_Leon.pdf

Chicago Manual of Style (16th Edition):

Leon, Otilia. “Improved oncological treatment of anal cancer.” 2019. Doctoral Dissertation, University of Lund. Accessed January 20, 2020. http://lup.lub.lu.se/record/fb100283-a48a-4886-88c3-c5654d33b5a3 ; https://portal.research.lu.se/ws/files/61679568/Improved_oncological_treatment_of_anal_cancer_Otilia_Leon.pdf.

MLA Handbook (7th Edition):

Leon, Otilia. “Improved oncological treatment of anal cancer.” 2019. Web. 20 Jan 2020.

Vancouver:

Leon O. Improved oncological treatment of anal cancer. [Internet] [Doctoral dissertation]. University of Lund; 2019. [cited 2020 Jan 20]. Available from: http://lup.lub.lu.se/record/fb100283-a48a-4886-88c3-c5654d33b5a3 ; https://portal.research.lu.se/ws/files/61679568/Improved_oncological_treatment_of_anal_cancer_Otilia_Leon.pdf.

Council of Science Editors:

Leon O. Improved oncological treatment of anal cancer. [Doctoral Dissertation]. University of Lund; 2019. Available from: http://lup.lub.lu.se/record/fb100283-a48a-4886-88c3-c5654d33b5a3 ; https://portal.research.lu.se/ws/files/61679568/Improved_oncological_treatment_of_anal_cancer_Otilia_Leon.pdf


University of Southern California

20. Wang, Ying. A comparison of methods for estimating survival probabilities in two stage phase III randomized clinical trials.

Degree: PhD, Biostatistics, 2009, University of Southern California

 As two stage randomized study designs gain increased recognition and popularity for oncology studies it remains a challenge to analyze and interpret clinical outcomes due… (more)

Subjects/Keywords: two stage design; bootstrap process; survival analysis; randomized clinical trial; induction therapy; maintenance therapy; oncology; phase III; COG; IPW; missing data

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Wang, Y. (2009). A comparison of methods for estimating survival probabilities in two stage phase III randomized clinical trials. (Doctoral Dissertation). University of Southern California. Retrieved from http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/214403/rec/130

Chicago Manual of Style (16th Edition):

Wang, Ying. “A comparison of methods for estimating survival probabilities in two stage phase III randomized clinical trials.” 2009. Doctoral Dissertation, University of Southern California. Accessed January 20, 2020. http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/214403/rec/130.

MLA Handbook (7th Edition):

Wang, Ying. “A comparison of methods for estimating survival probabilities in two stage phase III randomized clinical trials.” 2009. Web. 20 Jan 2020.

Vancouver:

Wang Y. A comparison of methods for estimating survival probabilities in two stage phase III randomized clinical trials. [Internet] [Doctoral dissertation]. University of Southern California; 2009. [cited 2020 Jan 20]. Available from: http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/214403/rec/130.

Council of Science Editors:

Wang Y. A comparison of methods for estimating survival probabilities in two stage phase III randomized clinical trials. [Doctoral Dissertation]. University of Southern California; 2009. Available from: http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll127/id/214403/rec/130


University of Michigan

21. Muenz, Daniel. New Statistical Methods for Phase I Clinical Trials of a Single Agent.

Degree: PhD, Biostatistics, 2017, University of Michigan

 The primary goal of phase I clinical trials in oncology is to determine a safe and possibly effective dose of a treatment, and to recommend… (more)

Subjects/Keywords: Phase 1 clinical trial; Biostatistics; Dose-limiting toxicity; Adaptive design; Public Health; Statistics and Numeric Data; Health Sciences; Science

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Muenz, D. (2017). New Statistical Methods for Phase I Clinical Trials of a Single Agent. (Doctoral Dissertation). University of Michigan. Retrieved from http://hdl.handle.net/2027.42/140847

Chicago Manual of Style (16th Edition):

Muenz, Daniel. “New Statistical Methods for Phase I Clinical Trials of a Single Agent.” 2017. Doctoral Dissertation, University of Michigan. Accessed January 20, 2020. http://hdl.handle.net/2027.42/140847.

MLA Handbook (7th Edition):

Muenz, Daniel. “New Statistical Methods for Phase I Clinical Trials of a Single Agent.” 2017. Web. 20 Jan 2020.

Vancouver:

Muenz D. New Statistical Methods for Phase I Clinical Trials of a Single Agent. [Internet] [Doctoral dissertation]. University of Michigan; 2017. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/2027.42/140847.

Council of Science Editors:

Muenz D. New Statistical Methods for Phase I Clinical Trials of a Single Agent. [Doctoral Dissertation]. University of Michigan; 2017. Available from: http://hdl.handle.net/2027.42/140847


University of Oxford

22. Copsey, Bethan. Improving the specification of the target difference in the sample size calculation of a randomised trial of treatments for osteoarthritis.

Degree: PhD, 2019, University of Oxford

 The sample size of a clinical trial is the number of participants the trial aims to recruit. Sample size is a critical aspect of clinical(more)

Subjects/Keywords: Osteoarthritis; Clinical trial; Sample size; Randomised trial

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Copsey, B. (2019). Improving the specification of the target difference in the sample size calculation of a randomised trial of treatments for osteoarthritis. (Doctoral Dissertation). University of Oxford. Retrieved from http://ora.ox.ac.uk/objects/uuid:ba147e47-6c0f-477b-89c5-a700b467d84a ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.791739

Chicago Manual of Style (16th Edition):

Copsey, Bethan. “Improving the specification of the target difference in the sample size calculation of a randomised trial of treatments for osteoarthritis.” 2019. Doctoral Dissertation, University of Oxford. Accessed January 20, 2020. http://ora.ox.ac.uk/objects/uuid:ba147e47-6c0f-477b-89c5-a700b467d84a ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.791739.

MLA Handbook (7th Edition):

Copsey, Bethan. “Improving the specification of the target difference in the sample size calculation of a randomised trial of treatments for osteoarthritis.” 2019. Web. 20 Jan 2020.

Vancouver:

Copsey B. Improving the specification of the target difference in the sample size calculation of a randomised trial of treatments for osteoarthritis. [Internet] [Doctoral dissertation]. University of Oxford; 2019. [cited 2020 Jan 20]. Available from: http://ora.ox.ac.uk/objects/uuid:ba147e47-6c0f-477b-89c5-a700b467d84a ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.791739.

Council of Science Editors:

Copsey B. Improving the specification of the target difference in the sample size calculation of a randomised trial of treatments for osteoarthritis. [Doctoral Dissertation]. University of Oxford; 2019. Available from: http://ora.ox.ac.uk/objects/uuid:ba147e47-6c0f-477b-89c5-a700b467d84a ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.791739


Universitat Autònoma de Barcelona

23. Rodón Ahnert, Jordi. Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer.

Degree: Departament de Medicina, 2015, Universitat Autònoma de Barcelona

 This work focuses on the role of biomarkers in the early development of drugs in oncology, and introduces a new concept such as the early… (more)

Subjects/Keywords: Fosfoinositol-3-quinasa; Phosohoinositol-3-kinase; Sonic Hedgehog; Ensayo clìnico fase I; Assaig clínic fase I; Pahse I clinical trial; Ciències de la Salut; 61

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Rodón Ahnert, J. (2015). Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer. (Thesis). Universitat Autònoma de Barcelona. Retrieved from http://hdl.handle.net/10803/305098

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Rodón Ahnert, Jordi. “Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer.” 2015. Thesis, Universitat Autònoma de Barcelona. Accessed January 20, 2020. http://hdl.handle.net/10803/305098.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Rodón Ahnert, Jordi. “Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer.” 2015. Web. 20 Jan 2020.

Vancouver:

Rodón Ahnert J. Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer. [Internet] [Thesis]. Universitat Autònoma de Barcelona; 2015. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/10803/305098.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Rodón Ahnert J. Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer. [Thesis]. Universitat Autònoma de Barcelona; 2015. Available from: http://hdl.handle.net/10803/305098

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Zululand

24. Mzimela, Adelaide Misiwe. Understanding the impact of participation in a microbicide clinical trial on condom use .

Degree: 2010, University of Zululand

 There is ongoing debate regarding the public health message of introducing a microbicide that is less efficacious than condoms into the HIV prevention field. One… (more)

Subjects/Keywords: Condom use ; microbicide clinical trial

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Mzimela, A. M. (2010). Understanding the impact of participation in a microbicide clinical trial on condom use . (Thesis). University of Zululand. Retrieved from http://hdl.handle.net/10530/609

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Mzimela, Adelaide Misiwe. “Understanding the impact of participation in a microbicide clinical trial on condom use .” 2010. Thesis, University of Zululand. Accessed January 20, 2020. http://hdl.handle.net/10530/609.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Mzimela, Adelaide Misiwe. “Understanding the impact of participation in a microbicide clinical trial on condom use .” 2010. Web. 20 Jan 2020.

Vancouver:

Mzimela AM. Understanding the impact of participation in a microbicide clinical trial on condom use . [Internet] [Thesis]. University of Zululand; 2010. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/10530/609.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Mzimela AM. Understanding the impact of participation in a microbicide clinical trial on condom use . [Thesis]. University of Zululand; 2010. Available from: http://hdl.handle.net/10530/609

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

25. Truong, Kathy. Evaluating Communication Channels and Practices Within and Across the Ardea Phase 3 Clinical Program .

Degree: 2013, California State University – San Marcos

 Ardea Biosciences, Inc., a wholly owned subsidiary of AstraZeneca, PLC., recently developed several gout drugs, with Lesinurad as the most advanced product candidate in Phase(more)

Subjects/Keywords: communication; project management; clinical trial

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Truong, K. (2013). Evaluating Communication Channels and Practices Within and Across the Ardea Phase 3 Clinical Program . (Thesis). California State University – San Marcos. Retrieved from http://hdl.handle.net/10211.8/421

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Truong, Kathy. “Evaluating Communication Channels and Practices Within and Across the Ardea Phase 3 Clinical Program .” 2013. Thesis, California State University – San Marcos. Accessed January 20, 2020. http://hdl.handle.net/10211.8/421.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Truong, Kathy. “Evaluating Communication Channels and Practices Within and Across the Ardea Phase 3 Clinical Program .” 2013. Web. 20 Jan 2020.

Vancouver:

Truong K. Evaluating Communication Channels and Practices Within and Across the Ardea Phase 3 Clinical Program . [Internet] [Thesis]. California State University – San Marcos; 2013. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/10211.8/421.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Truong K. Evaluating Communication Channels and Practices Within and Across the Ardea Phase 3 Clinical Program . [Thesis]. California State University – San Marcos; 2013. Available from: http://hdl.handle.net/10211.8/421

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University College Cork

26. Hurley, Caroline. Implementation of risk based monitoring into academic led clinical trials in Ireland.

Degree: 2018, University College Cork

 Introduction: In November 2016, the International Conference on Harmonsation (ICH) published a requirement for sponsors to develop a systematic, prioritised, risk-based approach to monitoring clinical(more)

Subjects/Keywords: Risk based monitoring; Clinical trial

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Hurley, C. (2018). Implementation of risk based monitoring into academic led clinical trials in Ireland. (Thesis). University College Cork. Retrieved from http://hdl.handle.net/10468/7967

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Hurley, Caroline. “Implementation of risk based monitoring into academic led clinical trials in Ireland.” 2018. Thesis, University College Cork. Accessed January 20, 2020. http://hdl.handle.net/10468/7967.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Hurley, Caroline. “Implementation of risk based monitoring into academic led clinical trials in Ireland.” 2018. Web. 20 Jan 2020.

Vancouver:

Hurley C. Implementation of risk based monitoring into academic led clinical trials in Ireland. [Internet] [Thesis]. University College Cork; 2018. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/10468/7967.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Hurley C. Implementation of risk based monitoring into academic led clinical trials in Ireland. [Thesis]. University College Cork; 2018. Available from: http://hdl.handle.net/10468/7967

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Washington

27. Guo, Yanshu. Effect of Time Measurement Error on Assessing Treatments with Time Dependent Effect.

Degree: 2017, University of Washington

 In the emergency medicine setting, it is often difficult to accurately record the time of injury without measurement error. If the treatment effect varies depending… (more)

Subjects/Keywords: Clinical Trial; TXA; Biostatistics; Biostatistics

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Guo, Y. (2017). Effect of Time Measurement Error on Assessing Treatments with Time Dependent Effect. (Thesis). University of Washington. Retrieved from http://hdl.handle.net/1773/40507

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Guo, Yanshu. “Effect of Time Measurement Error on Assessing Treatments with Time Dependent Effect.” 2017. Thesis, University of Washington. Accessed January 20, 2020. http://hdl.handle.net/1773/40507.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Guo, Yanshu. “Effect of Time Measurement Error on Assessing Treatments with Time Dependent Effect.” 2017. Web. 20 Jan 2020.

Vancouver:

Guo Y. Effect of Time Measurement Error on Assessing Treatments with Time Dependent Effect. [Internet] [Thesis]. University of Washington; 2017. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/1773/40507.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Guo Y. Effect of Time Measurement Error on Assessing Treatments with Time Dependent Effect. [Thesis]. University of Washington; 2017. Available from: http://hdl.handle.net/1773/40507

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Universiteit Utrecht

28. Boss, D.S. Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs.

Degree: 2009, Universiteit Utrecht

 With the emergence of novel, rationally designed anti-cancer drugs there is also a need for novel endpoints when evaluating these drugs in clinical trials. The… (more)

Subjects/Keywords: Farmacie; Drug Development; PET/CT; Phase I studies; Pharmacokinetics; Pharmacodynamics; Clinical trials; Cancer; Targeted therapy

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Boss, D. S. (2009). Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs. (Doctoral Dissertation). Universiteit Utrecht. Retrieved from http://dspace.library.uu.nl:8080/handle/1874/37369

Chicago Manual of Style (16th Edition):

Boss, D S. “Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs.” 2009. Doctoral Dissertation, Universiteit Utrecht. Accessed January 20, 2020. http://dspace.library.uu.nl:8080/handle/1874/37369.

MLA Handbook (7th Edition):

Boss, D S. “Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs.” 2009. Web. 20 Jan 2020.

Vancouver:

Boss DS. Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs. [Internet] [Doctoral dissertation]. Universiteit Utrecht; 2009. [cited 2020 Jan 20]. Available from: http://dspace.library.uu.nl:8080/handle/1874/37369.

Council of Science Editors:

Boss DS. Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs. [Doctoral Dissertation]. Universiteit Utrecht; 2009. Available from: http://dspace.library.uu.nl:8080/handle/1874/37369


University of Manitoba

29. Zhang, Weijia. Statistical design of phase I clinical trials.

Degree: Statistics, 2016, University of Manitoba

 My MSc thesis is focused on parametric designs of Phase I clinical trials, using the continual reassessment method. A parametric model with unknown parameters is… (more)

Subjects/Keywords: Phase I clinical trials; Continual reassessment method; Bayesian method; Toxicity; Maximum tolerated dose

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Zhang, W. (2016). Statistical design of phase I clinical trials. (Masters Thesis). University of Manitoba. Retrieved from http://hdl.handle.net/1993/31795

Chicago Manual of Style (16th Edition):

Zhang, Weijia. “Statistical design of phase I clinical trials.” 2016. Masters Thesis, University of Manitoba. Accessed January 20, 2020. http://hdl.handle.net/1993/31795.

MLA Handbook (7th Edition):

Zhang, Weijia. “Statistical design of phase I clinical trials.” 2016. Web. 20 Jan 2020.

Vancouver:

Zhang W. Statistical design of phase I clinical trials. [Internet] [Masters thesis]. University of Manitoba; 2016. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/1993/31795.

Council of Science Editors:

Zhang W. Statistical design of phase I clinical trials. [Masters Thesis]. University of Manitoba; 2016. Available from: http://hdl.handle.net/1993/31795


University of Manitoba

30. Zhang, Weijia. Novel statistical designs for phase I clinical trials.

Degree: Statistics, 2019, University of Manitoba

 A clinical trial is an experiment on human subjects designed to evaluate the safety and efficacy of a new drug or medical intervention. There are… (more)

Subjects/Keywords: Bayesian method; CRM; Maximum tolerated dose; Phase I clinical trials; Toxicity probability

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Zhang, W. (2019). Novel statistical designs for phase I clinical trials. (Thesis). University of Manitoba. Retrieved from http://hdl.handle.net/1993/34170

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Zhang, Weijia. “Novel statistical designs for phase I clinical trials.” 2019. Thesis, University of Manitoba. Accessed January 20, 2020. http://hdl.handle.net/1993/34170.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Zhang, Weijia. “Novel statistical designs for phase I clinical trials.” 2019. Web. 20 Jan 2020.

Vancouver:

Zhang W. Novel statistical designs for phase I clinical trials. [Internet] [Thesis]. University of Manitoba; 2019. [cited 2020 Jan 20]. Available from: http://hdl.handle.net/1993/34170.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Zhang W. Novel statistical designs for phase I clinical trials. [Thesis]. University of Manitoba; 2019. Available from: http://hdl.handle.net/1993/34170

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

[1] [2] [3] [4] [5] … [1546]

.